Skip to main content

Table 3 Comparison between COVID-19 patients with cancer and without cancer

From: Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study

Clinical features

All patients (n = 309)

Non-cancer patients (n = 206)

Cancer patients (n = 103)

P-value

Age

66.0 (20.0–95.0)

66.00 (20.00–95.00)

66.0 (24.0–90.0)

0.948

Gender

   

0.810

 Female

138 (44.7%)

91 (44.1%)

47 (45.6%)

 

 Male

171 (55.3%)

115 (55.8%)

56 (54.4%)

 

Comorbidities

    

 Diabetes

37 (11.9)

23 (11.1%)

14 (13.6%)

0.579

 Hypertension

96 (31.0%)

59 (28.6%)

37 (35.9%)

0.195

 Heart disease

41 (13.2)

30 (14.5%)

11 (10.7%)

0.379

Symptoms

    

 Fever

234 (74.7%)

161 (78.1)

73 (70.9%)

0.163

 Cough

207(66.9%)

137 (66.5%)

70 (68.0%)

0.898

 Dyspnea

45 (14.6%)

21 (10.2%)

24 (23.3%)

0.003

 Vomiting

10 (3.2%)

5 (2.4%)

5 (4.9%)

0.310

 Diarrhoea

17 (5.5)

10 (4.8%)

7 (6.8%)

0.597

Severity

   

0.520

 Non-severe

209 (67.6%)

142 (68.9%)

67 (65%)

 

 Severe

100 (32.4%)

64 (31%)

36 (35%)

 

Clinical outcome

   

0.028

 Survivor

288 (93.2%)

197 (95.6%)

91 (88.3%)

 

 Non-survivor

21 (6.8%)

9 (4.4%)

12 (11.7%)

 

Laboratory findings

    

 WBC (× 109/L)

5.50 (0.80–28.20); n = 306

5.60 (0.80–28.2); n = 206

5.29 (1.90–25.10); n = 100

0.381

 Neutrophil (× 109/L)

3.25 (0.44–26.07); n = 306

3.23 (0.44–26.07); n = 206

3.49 (0.67–22.40); n = 100

0.164

 Lymphocyte (× 109/L)

1.41 (0.60–3.50); n = 306

1.54 (0.60–3.50); n = 206

1.06 (0.22–2.89); n = 100

 < 0.001

 NLR

2.28 (0.20–62.12); n = 306

2.11 (0.20–62.12); n = 206

2.93 (0.64–32.23); n = 100

 < 0.001

 Monocytes (× 109/L)

0.48 (0.03–1.16); n = 278

0.50 (0.03–1.16); n = 206

0.43 (0.11–1.11); n = 72

0.040

 Eosnophils (× 109/L)

0.11 (0.00–0.90); n = 278

0.12 (0.00–0.72); n = 206

0.07 (0.00–0.90); n = 72

 < 0.001

 Basophils (× 109/L)

0.03 (0.00–0.11); n = 278

0.03 (0.00–0.08); n = 206

0.02 (0.00–0.11); n = 72

0.076

 RBC (× 1012/L)

3.93 (1.17–5.77); n = 279

3.93 (1.17–5.60); n = 206

3.95 (2.03–5.77); n = 73

0.406

 HB (g/L)

120.00 (53.00–166.00); n = 279

120.50 (53.00–166.00); n = 206

116.00 (68.00–154.00); n = 73

0.074

 PLT (× 109/L)

209.50 (4.00–443.00); n = 278

213.00 (4.00–443.00); n = 206

203.00 (53.00–431.00); n = 72

0.120

 CRP (mg/L)

2.27 (0 .01–280.32); n = 251

2.16 (0.01–268.60); n = 161

2.52 (0.14–280.32); n = 90

0.147

 ALT (U/L)

21.67 (4.50–239.70); n = 301

23.35 (5.30–239.70); n = 204

19.17 (4.50–131.20); n = 97

0.047

 AST (U/L)

21.55 (9.60–502.40); n = 260

21.51 (9.60–502.40); n = 176

21.70 (10.00–147.20); n = 84

0.374

 Total protein (g/L)

65.5 (32.70–87.58); n = 276

65.81 (32.70–81.6); n = 205

64.99 (53.70–87.58); n = 71

0.528

 Albumin (g/L)

37.30 (18.3–48.00); n = 276

37.36 (18.30–45.55); n = 205

37.29 (23.60–48.00); n = 71

0.723

 Globulin (g/L)

27.73 (14.40–46.24); n = 276

27.70 (14.40–45.91); n = 205

28.00 (17.31–46.24); n = 71

0.417

 A/G

1.33 (0.39–2.65); n = 276

1.33 (0.70–2.65); n = 205

1.30 (0.39–2.20); n = 71

0.338

 Total bilirubin (umol/L)

10.00 (4.20–415.70); n = 274

9.76 (4.20–415.70); n = 204

10.32 (4.20–44.58); n = 70

0.514

 Direct Bilirubin (umol/L)

2.50 (0.00–326.70); n = 274

2.50 (0.00–326.70); n = 204

2.71 (0.00–23.90); n = 70

0.412

 Indirect bilirubin (umol/L)

7.18 (2.69–89.01); n = 274

7.17 (2.69–89.01); n = 204

7.39 (2.99–26.42); n = 70

0.883

 BUN (umol/L)

4.88 (2.23–36.08); n = 272

4.93 (2.23–36.08); n = 204

4.67 (2.68–29.61); n = 68

0.471

 Creatinine (umol/L)

60.00 (13.25–345.35); n = 273

60.87 (26.77–243.40); n = 203

57.72 (13.25–345.35); n = 70

0.509

 Uric acid (umol/L)

281.63 (69.00–600.56); n = 273

286.02 (69.00–600.56); n = 204

268.01 (100.00–575.95); n = 69

0.274

 ALP (U/L)

71.10 (31.90–493.30); n = 272

71.12 (31.90–366.10); n = 202

71.10 (42.59–493.30); n = 70

0.461

 γ-GT (U/L)

26.50 (7.64–263.6); n = 273

26.50 (7.64–242.2); n = 203

26.47 (8.15–263.60); n = 70

0.813

 CK (U/L)

44.31 (10.90–1210.00); n = 229

43.20 (11.00–1210.00); n = 174

48.40 (10.90–195.90); n = 55

0.084

 LDH (U/L)

175.35 (2.17–1489.89); n = 270

174.10 (99.90–489.89); n = 201

179.90 (2.17–761.70); n = 69

0.686

 ɑ-HBDH (U/L)

130.30 (79.66–1028.00); n = 267

129.80 (79.66–1028.00); n = 201

133.59 (87.75–701.40); n = 66

0.511

 D-dimer (mg/L)

0.44 (0.01−27.94); n = 172

0.44 (0.01−6.91); n = 127

0.43 (0.02–27.94); n = 45

0.498

 NT-proBNP (U/L)

43.94 (0.01–35,000.00); n = 102

51.61 (0.01–35,000.00); n = 80

30.77 (0.01–515.18); n = 22

0.503

 Procalcitonin (ng/ml)

0.045 (0.01–87.04); n = 200

0.042 (0.01–87.04); n = 144

0.05 (0.02–0.90); n = 56

0.231

 IL-6 (pg/ml)

3.20 (1.50–5000.00); n = 189

3.0 (1.50–5000.00); n = 139

3.64 (1.50–3392.00); n = 50

0.099

  1. WBC white blood cell, NLR leukocyte to lymphocyte ratio, RBC red blood cell, HB hemoglobin, PLT platelet, CRP C-reactive protein, ALT alanine transaminase, AST aspartate transaminase, A/G albumin to globulin ratio, BUN blood urea nitrogen, ALP alkaline phosphatase, γ-GT gamma-glutamyl transpeptidase, CK creatine kinase, CKMB MB isoenzyme of creatine kinase, LDH lactate dehydrogenase, α-HBDH alpha-hydroxybutyric dehydrogenase, NT-proBNP N-terminal pro brain natriuretic peptide, IL-6 interleukin-6